Combination therapy of milrinone and esmolol on heart function, inflammatory factors and prognosis of sepsis patients

王曾庚,吴清华,聂祥碧,郭经华
DOI: https://doi.org/10.3969/j.issn.1002-1949.2015.07.002
2015-01-01
Abstract:Objective We aimed to investigate the safety of combination therapy with milrinone and esmolol on heart protection and prognosis improvement in patients with sepsis .Methods Ninety subjects with sepsis were consecutively recruited and randomly divided into control ( C) , milrinone ( M) and milrinone-esmolol ( ME) groups.Cardiac function indexes such as cardiac index ( CI), stroke volume index ( SVI ) , mean arterial pressure ( MAP ) , central venous pressure ( CVP ) , heart rate (HR), PaO2/FiO2 ratio and blood lactic acid (Lac) level were detected.In addition, the serum levels of proinflammatory factors ( including TNF -α, IL-6 and HMGB -1 ) and myocardial injury makers (including CK-MB, cTnI and BNP) were also tested by ELISA.Results There was no difference in all measured indexes before treatment .After combination therapy , no difference in MAP , CVP and PaO2/FiO2 was observed .However , 12 hours after treatment , the HR of patients in ME group was lower than that of patients in C and M groups , while the Lac level of M and ME groups was lower than that of C group 48 hours later.Similarly, the CI and SVI levels in M and ME groups were higher than those in C group at 12 hours after treatment , while the serum levels of proinflammatory factors and makers of myocardial injury in ME group were lower compared with C and M groups at 24 hours after treatment . Patients in ME group had higher 28-day survival rate and better compliance rate of HR than the other two groups.Conclusion Combination therapy with milrinone and esmolol could improve cardiac function and 28-day survival rate as well as inhibit the inflammatory response and myocardial injury in patients with severe sepsis .
What problem does this paper attempt to address?